These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 23318765)
1. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chen B; Cao F; Yuan C; Lu X; Shen S; Zhou J; Le XC Anal Bioanal Chem; 2013 Feb; 405(6):1903-11. PubMed ID: 23318765 [TBL] [Abstract][Full Text] [Related]
2. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Wang Z; Zhou J; Lu X; Gong Z; Le XC Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923 [TBL] [Abstract][Full Text] [Related]
3. Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. Iriyama N; Yoshino Y; Yuan B; Horikoshi A; Hirabayashi Y; Hatta Y; Toyoda H; Takeuchi J J Hematol Oncol; 2012 Jan; 5():1. PubMed ID: 22272800 [TBL] [Abstract][Full Text] [Related]
4. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Yoshino Y; Yuan B; Miyashita SI; Iriyama N; Horikoshi A; Shikino O; Toyoda H; Kaise T Anal Bioanal Chem; 2009 Jan; 393(2):689-97. PubMed ID: 19009285 [TBL] [Abstract][Full Text] [Related]
5. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide. Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921 [TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Fukai Y; Hirata M; Ueno M; Ichikawa N; Kobayashi H; Saitoh H; Sakurai T; Kinoshita K; Kaise T; Ohta S Biol Pharm Bull; 2006 May; 29(5):1022-7. PubMed ID: 16651738 [TBL] [Abstract][Full Text] [Related]
7. Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment. Chen B; Cao F; Lu X; Shen S; Zhou J; Le XC Talanta; 2018 Jul; 184():446-451. PubMed ID: 29674067 [TBL] [Abstract][Full Text] [Related]
8. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide. Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697 [TBL] [Abstract][Full Text] [Related]
9. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation. Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848 [TBL] [Abstract][Full Text] [Related]
10. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide. Zhang Z; Chen Y; Meng H; Sui M; Zhou Q; Shi C; Han L; Wang H; Zhou J Leuk Lymphoma; 2013 Sep; 54(9):2041-6. PubMed ID: 23343178 [TBL] [Abstract][Full Text] [Related]
12. Arsenic speciation analysis in human saliva. Yuan C; Lu X; Oro N; Wang Z; Xia Y; Wade TJ; Mumford J; Le XC Clin Chem; 2008 Jan; 54(1):163-71. PubMed ID: 17981925 [TBL] [Abstract][Full Text] [Related]
13. Speciation analysis of arsenic in urine samples from APL patients treated with single agent As Guo M; Li J; Fan S; Liu W; Wang B; Gao C; Zhou J; Hai X J Pharm Biomed Anal; 2019 Jul; 171():212-217. PubMed ID: 31009876 [TBL] [Abstract][Full Text] [Related]
14. Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide. Gao C; Lin L; Li J; Wu M; Lv J; Tian S; Hai X Toxicol Lett; 2023 May; 380():31-39. PubMed ID: 37024065 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic Properties of Arsenic Species after Intravenous and Intragastrical Administration of Arsenic Trioxide Solution in Cynomolgus Macaques Using HPLC-ICP-MS. Shi Q; Ju M; Zhu X; Gan H; Gu R; Wu Z; Meng Z; Dou G Molecules; 2019 Jan; 24(2):. PubMed ID: 30634677 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of arsenic species in leukocytes and granulocytes of acute promyelocytic leukemia patients treated with arsenic trioxide. Wang X; Qian Z; Li H; Chen H; Lin L; Guo M; Hai X J Pharm Biomed Anal; 2021 Sep; 203():114201. PubMed ID: 34130006 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Gao C; Hu S; Guo M; Hai X; Zhou J Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392 [TBL] [Abstract][Full Text] [Related]
18. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573 [TBL] [Abstract][Full Text] [Related]
19. Species variations in the biliary and urinary excretion of arsenate, arsenite and their metabolites. Csanaky I; Gregus Z Comp Biochem Physiol C Toxicol Pharmacol; 2002 Mar; 131(3):355-65. PubMed ID: 11912060 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]